1. Gonadotrophin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: a multi-center randomized trial.
- Author
-
Granese R, Perino A, Calagna G, Saitta S, De Franciscis P, Colacurci N, Triolo O, and Cucinella G
- Subjects
- Adolescent, Adult, Drug Combinations, Estradiol therapeutic use, Female, Humans, Italy, Middle Aged, Nandrolone therapeutic use, Pain Management, Pain Measurement, Prospective Studies, Quality of Life, Recurrence, Surveys and Questionnaires, Endometriosis surgery, Estradiol analogs & derivatives, Gonadotropin-Releasing Hormone analogs & derivatives, Laparoscopy, Nandrolone analogs & derivatives, Pelvic Pain etiology, Pelvic Pain prevention & control
- Abstract
Objectives: To evaluate the efficacy of dienogest + estradiol valerate (E2V) and gonadotrophin-releasing hormone analogue (GnRH-a) in reducing recurrence of pain in patients with chronic pelvic pain due to laparoscopically diagnosed and treated endometriosis., Design: Multi-center, prospective, randomized study., Setting: Three university departments of obstetrics and gynecology in Italy., Population: Seventy-eight women who underwent laparoscopic surgery for endometriosis combined with chronic pelvic pain., Methods: Post-operative administration of dienogest + E2V for 9 months (group 1) or GnRH-a monthly for 6 months (group 2)., Main Outcome Measures: A visual analogue scale was used to test intensity of pain before laparoscopic surgery at 3, 6 and 9 months of follow up. A questionnaire to investigate quality of life was administered before surgery and at 9 months of follow up., Results: The visual analogue scale score did not show any significant differences between the two groups (p = 0.417). The questionnaire showed an increase of scores for all women compared with pre-surgery values, demonstrating a marked improvement in quality of life and health-related satisfaction with both treatments. No significant differences were found between the groups. The rate of apparent endometriosis recurrence was 10.8% in group 1 and 13.7% in group 2 (p = 0.962)., Conclusion: Both therapies seemed equally efficacious in preventing endometriosis-related chronic pelvic pain recurrence in the first 9 months of follow-up., (© 2015 Nordic Federation of Societies of Obstetrics and Gynecology.)
- Published
- 2015
- Full Text
- View/download PDF